ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC is a biotechnology company that discovers and develops small molecule drugs for virology and immunology conditions using a chemistry-driven approach. In virology, the company discovered glecaprevir, an antiviral protease inhibitor developed through a collaboration with AbbVie for treating hepatitis C virus (HCV). Glecaprevir is a component of AbbVie's direct-acting antiviral combination treatment, marketed as MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir) since 2017 for chronic HCV. MAVYRET® was also approved in June 2025 as the first and only treatment for acute HCV infection. ENANTA PHARMACEUTICALS INC's active virology development programs focus on respiratory syncytial virus (RSV), a common cause of bronchiolitis and pneumonia, and a leading cause of U.S. hospitalization in young children and respiratory illness in older adults. High-risk populations for severe RSV infection include infants, young children, adults over 65, and individuals with chronic heart or lung disease. Recent CDC estimates indicate a significant RSV burden in the U.S., with up to 6.5 million outpatient visits, 350,000 hospitalizations, and 23,000 deaths annually. The company also has clinical-stage virology programs for SARS-CoV-2, which causes COVID-19, and Hepatitis B virus (HBV). In immunology, ENANTA PHARMACEUTICALS INC designs and develops potent and selective oral small molecule inhibitors to treat type 2 inflammatory diseases by targeting immune response mechanisms. An overactive immune response drives various inflammatory diseases with unmet needs, including atopic dermatitis (AD), urticarias, asthma, prurigo nodularis (PN), chronic rhinosinusitis with nasal polyps (CRSwNP), some forms of chronic obstructive pulmonary disease (COPD), and other conditions.